PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ozanimod - Inflammatory bowel disease

PAD Profile : Ozanimod - Inflammatory bowel disease Important

Keywords :
Ulcerative colitis, UC, sphingosine 1-phosphate (S1P) receptor modulator, IBD,
Brand Names Include :
Zeposia
Important Information :
Ulcerative Colitis - adults only.

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Capsules
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
ICB
BlueTeq
NICE
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Guidelines (Local)
IBD - High Cost Immunomodulator Pathway April 2024.pdf
Evidence Review
Ozanimod in UC NICE TA828 Briefing paper 07Dec22.pdf
Webpage
NICE TA828 - Ozanimod for treating moderately to severely active ulcerative colitis - October 2022

Committee Recommendations

Date
Committee Name
Narrative
04 October 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

04 January 2023
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approves ozanimod as recommended by NICE TA828 as an option for treating moderately to severely active ulcerative colitis in adults, only if:
•    conventional treatment cannot be tolerated or is not working well enough, and infliximab is not suitable, or
•    biological treatment cannot be tolerated or is not working well enough, and
•    the company provides it according to the commercial arrangement.

Ozanimod for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More